Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 21,100 shares, a decrease of 55.8% from the May 31st total of 47,700 shares. Based on an average daily trading volume, of 843,700 shares, the short-interest ratio is currently 0.0 days. Approximately 0.5% of the company’s shares are sold short.

Aptevo Therapeutics Price Performance

Shares of NASDAQ APVO traded down $0.21 during trading on Friday, hitting $0.31. 2,524,907 shares of the company traded hands, compared to its average volume of 158,767. The business’s fifty day moving average is $0.76 and its 200 day moving average is $4.11. Aptevo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $80.96.

Aptevo Therapeutics (NASDAQ:APVO) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($14.10) by $4.15. Equities research analysts anticipate that Aptevo Therapeutics will post -8.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Aptevo Therapeutics in a research report on Thursday, April 18th. They issued a “sell” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,235,000 shares of the biotechnology company’s stock, valued at approximately $408,000. Armistice Capital LLC owned 10.72% of Aptevo Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.